跳到正文
心血管健康證據回顧3 分鐘閱讀

降壓藥:收縮壓每降低5 mm Hg,主要心血管事件風險約降低10%

MoveVitals 編輯部 · 研究發表 · 解讀更新

原文:Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. · Lancet (London, England) · 2021 · 論文原文 ↗

先看重點

在48項隨機試驗共344716名參與者中,藥物使收縮壓降低5 mm Hg,可降低主要心血管事件的風險(無既往心血管疾病者風險比0.91,有既往心血管疾病者0.89),起始血壓為正常或正常高值時同樣如此。這些試驗發表於1972年至2013年,中位追蹤4.15年,無法反映長期效果和當代診療情況。

證據類型

證據回顧

解讀依據

公開摘要

閱讀重點

方法與適用範圍

研究在問什麼

對於血壓已處於正常或正常高值的人,無論是否已有心血管疾病,藥物降壓是否有益尚不明確。研究者彙總隨機試驗的個體參與者資料,觀察治療對主要心血管事件的影響如何隨起始收縮壓而變化。

研究對象與方法

個體參與者水平資料統合分析,納入48項隨機試驗,比較降壓藥與安慰劑或其他類別降壓藥,或強化與非強化降壓方案,每組追蹤均不少於1000人年。僅針對心力衰竭或急性期短期介入的試驗被排除。降壓治療試驗者協作組獲得了51項發表於1972年至2013年的研究資料。按是否有既往心血管疾病,並在七個收縮壓分層(從<120到≥170 mm Hg)中分析療效。主要結局為主要心血管事件(致死和非致死性中風、心肌梗死或缺血性心臟病,或導致死亡或住院的心力衰竭),按意向性治療分析。經費來自英國心臟基金會、英國國家衛生研究院和牛津馬丁學院。

主要發現

以下為作者報告的結果。數值須連同族群和不確定性一起閱讀。

  1. 1
    資料涵蓋344716名參與者(157728人有既往心血管疾病,186988人沒有)。中位追蹤4.15年後,42324人(12.3%)至少發生一次主要心血管事件。
  2. 2
    收縮壓每降低5 mm Hg,無既往心血管疾病者的風險比為0.91(95%置信區間0.89-0.94),有既往心血管疾病者為0.89(95%置信區間0.86-0.92)。
  3. 3
    每1000人年發病率:無既往心血管疾病者對照組31.9、介入組25.9;有既往心血管疾病者分別為39.7和36.0。
  4. 4
    沒有可靠證據表明療效因基線心血管疾病狀態或收縮壓分層而不同。治療前,有既往疾病者中19.8%、無既往疾病者中8.0%的收縮壓低於130 mm Hg。

限制與不確定性

  1. 1
    試驗跨越1972年至2013年,之後的基礎治療和用藥情況已有變化。
  2. 2
    中位追蹤僅4.15年,更長期的效果未知。
  3. 3
    「獲益不隨基線血壓而變化」來自亞組分析,統計效能低於總體分析。
  4. 4
    摘要未報告藥物不良反應,而這對血壓正常者的治療尤為重要。本解讀僅基於摘要。

日常健康啟示

該分析支援在試驗族群中,無論是否患有心血管疾病,藥物降壓帶來的相對獲益相近,作者認為溝通時應強調降低心血管風險本身。是否開始或調整降壓藥,應由本人與醫師共同決定。

如何連結自己的資料

經過驗證的上臂式血壓計是合適的家用工具:每次在相同時間、坐位休息後測量,看數天到數週的平均值,而不是單次讀數。腕戴裝置的血壓估算不等同於袖帶測量值。

如何理解這類證據

先看納入了哪些設計、文獻搜尋與偏誤評估如何完成,以及搜尋截止日期;發表新不代表底層證據都是最新的。

作者的結構化摘要 English

以下英文摘要依所記錄的開放授權轉載,屬於作者原始材料,並非 MoveVitals 解讀。上方已提供研究解讀,分別說明作者結果與本站解釋;重要結論可直接查核原文。

Background

The effects of pharmacological blood pressure lowering at normal or high-normal blood pressure ranges in people with or without pre-existing cardiovascular disease remains uncertain. We analysed individual participant data from randomised trials to investigate the effects of blood pressure lowering treatment on the risk of major cardiovascular events by baseline levels of systolic blood pressure.

Methods

We did a meta-analysis of individual participant-level data from 48 randomised trials of pharmacological blood pressure lowering medications versus placebo or other classes of blood pressure-lowering medications, or between more versus less intensive treatment regimens, which had at least 1000 persons-years of follow-up in each group. Trials exclusively done with participants with heart failure or short-term interventions in participants with acute myocardial infarction or other acute settings were excluded. Data from 51 studies published between 1972 and 2013 were obtained by the Blood Pressure Lowering Treatment Trialists' Collaboration (Oxford University, Oxford, UK). We pooled the data to investigate the stratified effects of blood pressure-lowering treatment in participants with and without prevalent cardiovascular disease (ie, any reports of stroke, myocardial infarction, or ischaemic heart disease before randomisation), overall and across seven systolic blood pressure categories (ranging from <120 to ≥170 mm Hg). The primary outcome was a major cardiovascular event (defined as a composite of fatal and non-fatal stroke, fatal or non-fatal myocardial infarction or ischaemic heart disease, or heart failure causing death or requiring admission to hospital), analysed as per intention to treat.

Findings

Data for 344 716 participants from 48 randomised clinical trials were available for this analysis. Pre-randomisation mean systolic/diastolic blood pressures were 146/84 mm Hg in participants with previous cardiovascular disease (n=157 728) and 157/89 mm Hg in participants without previous cardiovascular disease (n=186 988). There was substantial spread in participants' blood pressure at baseline, with 31 239 (19·8%) of participants with previous cardiovascular disease and 14 928 (8·0%) of individuals without previous cardiovascular disease having a systolic blood pressure of less than 130 mm Hg. The relative effects of blood pressure-lowering treatment were proportional to the intensity of systolic blood pressure reduction. After a median 4·15 years' follow-up (Q1-Q3 2·97-4·96), 42 324 participants (12·3%) had at least one major cardiovascular event. In participants without previous cardiovascular disease at baseline, the incidence rate for developing a major cardiovascular event per 1000 person-years was 31·9 (95% CI 31·3-32·5) in the comparator group and 25·9 (25·4-26·4) in the intervention group. In participants with previous cardiovascular disease at baseline, the corresponding rates were 39·7 (95% CI 39·0-40·5) and 36·0 (95% CI 35·3-36·7), in the comparator and intervention groups, respectively. Hazard ratios (HR) associated with a reduction of systolic blood pressure by 5 mm Hg for a major cardiovascular event were 0·91, 95% CI 0·89-0·94 for partipants without previous cardiovascular disease and 0·89, 0·86-0·92, for those with previous cardiovascular disease. In stratified analyses, there was no reliable evidence of heterogeneity of treatment effects on major cardiovascular events by baseline cardiovascular disease status or systolic blood pressure categories.

Interpretation

In this large-scale analysis of randomised trials, a 5 mm Hg reduction of systolic blood pressure reduced the risk of major cardiovascular events by about 10%, irrespective of previous diagnoses of cardiovascular disease, and even at normal or high-normal blood pressure values. These findings suggest that a fixed degree of pharmacological blood pressure lowering is similarly effective for primary and secondary prevention of major cardiovascular disease, even at blood pressure levels currently not considered for treatment. Physicians communicating the indication for blood pressure lowering treatment to their patients should emphasise its importance on reducing cardiovascular risk rather than focusing on blood pressure reduction itself.

Funding

British Heart Foundation, UK National Institute for Health Research, and Oxford Martin School.

來源與署名

Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis.

Blood Pressure Lowering Treatment Trialists' Collaboration.

Lancet (London, England) · 2021-05-01

DOI: 10.1016/s0140-6736(21)00590-0 ↗PubMed · 33933205 ↗Europe PMC · 所記錄的開放授權: cc by ↗

摘要著作權歸原作者,依來源紀錄的開放授權轉載。中文譯文協助閱讀,英文摘要供查核術語及具體數值;本站的方法學解釋與作者結論分別呈現。

MoveVitals 編輯解讀 · 健康教育內容 · 未記錄個人臨床審閱

來源查核日期 2026-11-01

實用健康指南

放在一起讀

·觀察研究統合分析

晝夜活動節律紊亂與更高的死亡風險相關(109,365人)

在7項觀察性研究、共109,365名參與者中,晝夜活動對比較弱(相對振幅較低)與更高的心血管死亡風險(風險比[HR]1.50,95%置信區間1.13至1.98)和全因死亡風險(HR 1.46,95%置信區間1.27至1.68)相關。證據基礎小,又是觀察性的,不能說明改善節律就能降低風險,疾病本身也可能擾亂節律。

Journal of the American Heart Association

重點論文精講閱讀論文 →
·隨機試驗統合分析

五類運動都降低了靜息血壓,等長訓練降幅最大

彙總270項隨機試驗、共15,827名參與者的結果,有氧、抗阻、聯合、間歇和等長訓練與無介入對照組相比都降低了靜息血壓(各P<0.001),其中等長訓練降幅最大:收縮壓下降8.24 mm Hg,舒張壓下降4.00 mm Hg。各方式之間的排序部分來自間接比較,各試驗也不盡相同,所以排序不是個人的運動處方。

British Journal of Sports Medicine

重點論文精講閱讀論文 →
·隨機對照試驗

鹽替代品使中國農村高危族群的中風、主要心血管事件和死亡率下降

在中國農村600個村莊、20,995名有中風史或年齡在60歲及以上且有高血壓的人中,使用鹽替代品(氯化鈉75%、氯化鉀25%)的中風發生率低於普通鹽:平均追蹤4.74年,每1000人年29.14次對33.65次(率比0.86,95%置信區間0.77至0.96;P=0.006)。死亡也更低(率比0.88),嚴重高鉀血癥事件沒有顯著增多,但試驗為開放標籤設計,且在中國農村開展。

The New England Journal of Medicine

重點論文精講閱讀論文 →
·測量驗證研究/回顧

智慧手錶脈搏不規則提醒較少見,做貼片檢查者34%確有房顫

在419,297名沒有已知心房顫動(房顫)的蘋果手錶使用者中,0.52%收到脈搏不規則提醒;返還可用心電貼片的450人中,34%確認有房顫(97.5%置信區間29至39)。提醒發出時恰有貼片記錄的,通知的陽性預測值為0.84(95%置信區間0.76至0.92),但收到提醒者中僅20.8%返還了貼片,沒有收到提醒的人未被監測,所以手錶沒有提醒並不能排除房顫。

The New England Journal of Medicine

重點論文精講閱讀論文 →
心血管健康 →